China Meheco To Acquire Huali Jiuzhou
This article was originally published in PharmAsia News
China Meheco will pay RMB 80 million to acquire 100 percent stake of Beijing Huali Jiuzhou Medicine, a major health care product distributor jointly owned by HolleyPharm and Zhejiang Hua Li Medicine Investment Group. The move represents China Meheco's attempt to shift from a foreign medical trading enterprise to an integrated foreign and domestic trading company. With the acquisition, it can quickly establish drug distribution channels in the nation's major cities to cover almost all grade-three hospitals. This has a strategic significance for the firm to seize domestic market share. When the deal is completed, China Meheco's core business revenue will increase by RMB 1 billion, elevating its position in the local pharmaceutical sector. (Click here for more - Chinese Language)
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.